Ryan Savitz, who serves as executive vice president, chief financial officer and chief business officer of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), executed insider transactions on March 31, 2026 that together moved a material amount of company equity.
On that date Savitz sold 91,847 shares of Dianthus common stock, realizing total proceeds of approximately $9.5 million. Reported sale prices for the disposals ranged between $78.33 and $85.54 per share.
Also on March 31, 2026, Savitz exercised stock options to acquire 114,367 shares of common stock. The option exercises were executed at strike prices of $8.44 and $17.88 and involved total cash required of $1,342,857.
Company filings indicate these sales and option exercises occurred pursuant to a pre-arranged trading arrangement under Rule 10b5-1, a plan that Savitz adopted on December 30, 2025.
Market commentary included an InvestingPro analysis noting that DNTH appears overvalued at current levels and pointing investors to its Fair Value analysis and a set of 16 additional InvestingPro Tips for further context.
These insider moves came amid a large equity raise by the company. Dianthus completed a public offering that brought in roughly $719 million in gross proceeds. The offering included the sale of 8,470,989 shares of common stock at $81.00 per share, a figure that reflects the inclusion of additional shares purchased by the underwriters. In conjunction with the common shares, Dianthus issued pre-funded warrants exercisable for up to 402,468 shares at a price of $80.999 per warrant.
Brokerage coverage remained active around the company. William Blair reiterated an Outperform rating on Dianthus after an FDA update removed certain safety screening criteria for the company’s claseprubart clinical trials, a regulatory change described as addressing concerns about drug-induced lupus in the drug’s development path. Separately, William Blair also cited interim results from the CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy, noting the trial’s interim efficacy and safety outcomes as competitive.
Wells Fargo maintained its Overweight rating on the stock and retained a $135.00 price target.
Taken together, the insider transactions, the equity offering and the analyst activity underline continued market engagement with Dianthus Therapeutics. Observers and investors will likely weigh the insider sales and option exercises, the fresh capital infusion and analyst sentiment when assessing the company’s near-term financing and valuation dynamics.